Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more
Market Cap & Net Worth: Newron Pharmaceuticals S.p.A. (0QOI)
Newron Pharmaceuticals S.p.A. (LSE:0QOI) has a market capitalization of $353.62 Million (£289.08 Million) as of March 18, 2026. Listed on the LSE stock exchange, this UK-based company holds position #12923 globally and #268 in its home market, demonstrating a -8.19% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Newron Pharmaceuticals S.p.A.'s stock price £16.20 by its total outstanding shares 17844300 (17.84 Million).
Newron Pharmaceuticals S.p.A. Market Cap History: 2026 to 2026
Newron Pharmaceuticals S.p.A.'s market capitalization history from 2026 to 2026. Data shows growth from $353.62 Million to $353.62 Million (0.00% CAGR).
Newron Pharmaceuticals S.p.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Newron Pharmaceuticals S.p.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 0QOI by Market Capitalization
Companies near Newron Pharmaceuticals S.p.A. in the global market cap rankings as of March 18, 2026.
Key companies related to Newron Pharmaceuticals S.p.A. by market ranking:
- Semapa (LS:SEM): Ranked #12914 globally with a market cap of $296.44 Million USD ( €288.80 Million EUR).
- CapitaLand Malaysia Mall Trust (KLSE:5180): Ranked #12915 globally with a market cap of $296.36 Million USD ( RM1.33 Billion MYR).
- Alma Media Oyj (HE:ALMA): Ranked #12924 globally with a market cap of $295.78 Million USD ( €288.15 Million EUR).
- PetroVietnam Power Nhon Trach 2 JSC (VN:NT2): Ranked #12925 globally with a market cap of $295.72 Million USD ( ₫7.51 Trillion VND).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #12914 | Semapa | LS:SEM | $296.44 Million | €21.55 |
| #12915 | CapitaLand Malaysia Mall Trust | KLSE:5180 | $296.36 Million | RM0.65 |
| #12924 | Alma Media Oyj | HE:ALMA | $295.78 Million | €13.50 |
| #12925 | PetroVietnam Power Nhon Trach 2 JSC | VN:NT2 | $295.72 Million | ₫25950.00 |
Newron Pharmaceuticals S.p.A. Historical Marketcap From 2026 to 2026
Between 2026 and today, Newron Pharmaceuticals S.p.A.'s market cap moved from $353.62 Million to $ 353.62 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | £353.62 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Newron Pharmaceuticals S.p.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $353.62 Million USD |
| MoneyControl | $353.62 Million USD |
| MarketWatch | $353.62 Million USD |
| marketcap.company | $353.62 Million USD |
| Reuters | $353.62 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.